PressOctober 31, 2024 Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group’s Stake in PsyLabs
PressOctober 31, 2024 MindBio Reports a 72% Reduction in Severity of Depression Sustained Six Months After Treatment in Clinical Trials
PressOctober 31, 2024 Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance
PressOctober 24, 2024 Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program
PressOctober 24, 2024 Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care
PressOctober 24, 2024 Mindbio Announces Clinical Trial Milestone In Phase 2B Microdosing Trials Targeting Existential Distress, Depression & Anxiety In Advanced Stage Cancer
PressOctober 23, 2024 Optimi Health Announces First PTSD Patients Treated with MDMA Capsules in Australia
PressOctober 22, 2024 Mindbio Completes Final Post Treatment Milestone in Phase 2A Microdosing Depression Clinical Trial
PressOctober 18, 2024 Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development
PressOctober 17, 2024 Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA™ Technology
PressOctober 16, 2024 Awakn Partners with the University of Nottingham for in Vivo Testing of Aminoindane New Chemical Entity (NCE) Pre-Clinical Program
PressOctober 15, 2024 Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical
PressOctober 10, 2024 Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site
PressOctober 10, 2024 Braxia Scientific Announces Voting Results from the Annual General and Special Meeting of Shareholders
PressOctober 10, 2024 Clearmind Medicine : FDA approval for the IND submission to conduct its trial already secured Form 6K
PressOctober 9, 2024 PharmAla to supply the University of Texas, San Antonio, with novel dosage form of LaNeo™ MDMA
PressOctober 9, 2024 MindBio Develops Long Term Shelf-Stable Microdosing Formulation and is Progressing in Multiple Phase 2B Clinical Trials
